Compare PVH & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PVH | CYTK |
|---|---|---|
| Founded | 1881 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 8.0B |
| IPO Year | N/A | 2004 |
| Metric | PVH | CYTK |
|---|---|---|
| Price | $75.75 | $63.35 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 15 |
| Target Price | ★ $93.43 | $77.87 |
| AVG Volume (30 Days) | 929.2K | ★ 1.8M |
| Earning Date | 12-03-2025 | 11-05-2025 |
| Dividend Yield | ★ 0.20% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 6.69 | N/A |
| Revenue | ★ $8,816,700,000.00 | $87,211,000.00 |
| Revenue This Year | $3.63 | $361.33 |
| Revenue Next Year | $2.20 | $65.14 |
| P/E Ratio | $11.34 | ★ N/A |
| Revenue Growth | 0.52 | ★ 2609.26 |
| 52 Week Low | $59.28 | $29.31 |
| 52 Week High | $111.71 | $69.33 |
| Indicator | PVH | CYTK |
|---|---|---|
| Relative Strength Index (RSI) | 43.60 | 50.08 |
| Support Level | $74.21 | $59.56 |
| Resistance Level | $88.61 | $67.26 |
| Average True Range (ATR) | 3.26 | 2.45 |
| MACD | -0.54 | -0.77 |
| Stochastic Oscillator | 8.37 | 39.05 |
PVH designs and markets branded apparel in more than 40 countries. Its key fashion categories include men's dress shirts, ties, sportswear, underwear, and jeans. Its two designer brands, Calvin Klein and Tommy Hilfiger, now generate practically all its revenue after its recent disposition of most of its smaller brands. PVH operates e-commerce sites, about 1,400 stores, and about 1,500 shop-in-shops and concessions. The firm also licenses its brands to third parties and distributes its merchandise through department stores and other wholesale accounts. PVH traces its history to 1881 and is based in New York City.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.